NASDAQ:PROF

Profound Medical (PROF) Stock Forecast, Price & News

$9.93

+0.10 (+1.02%)

(As of 12:45 PM ET)

Compare

Today's Range: $9.74
▼
$10.20
50-Day Range: $7.91
▼
$12.68
52-Week Range: $3.10
▼
$15.49

Volume: 4,588 shs
Average Volume: 26,759 shs
Market Capitalization: $212.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.63

Profound Medical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 28.3% Upside
$12.63 Price Target
Short Interest: Bearish
0.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.29) to ($1.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

854th out of 970 stocks

Surgical & Medical Instruments Industry

88th out of 101 stocks

3.5

Analyst's Opinion

Consensus Rating
Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.63, Profound Medical has a forecasted upside of 28.3% from its current price of $9.84.
Amount of Analyst Coverage
Profound Medical has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.87% of the outstanding shares of Profound Medical have been sold short.
Short Interest Ratio / Days to Cover
Profound Medical has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Profound Medical has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Profound Medical does not currently pay a dividend.
Dividend Growth
Profound Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PROF.

2.4

News and Social Media Coverage

News Sentiment
Profound Medical has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Profound Medical this week, compared to 1 article on an average week.
MarketBeat Follows
6 people have added Profound Medical to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Profound Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.52% of the stock of Profound Medical is held by insiders.
Percentage Held by Institutions
Only 35.91% of the stock of Profound Medical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Profound Medical are expected to grow in the coming year, from ($1.29) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Profound Medical is -7.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Profound Medical is -7.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Profound Medical has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Profound Medical (NASDAQ:PROF) Stock

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF Price History

30 days | 90 days | 365 days | Advanced Chart

PROF Stock News Headlines

September 26, 2023 | markets.businessinsider.com

TD SYNNEX, Profound Medical And 3 Stocks To Watch Heading Into Tuesday

September 26, 2023 | msn.com

US FDA grants clearance for Profound’s Thermal Boost module

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

September 25, 2023 | marketwatch.com

Profound Medical Shares Rise 8.7% After FDA Gives Clearance for TULSA-PRO Thermal Boost

September 25, 2023 | markets.businessinsider.com

Profound Medical Secures FDA 510(k) Clearance For Thermal Boost Module

September 25, 2023 | financialpost.com

Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost

September 22, 2023 | americanbankingnews.com

Raymond James Weighs in on Profound Medical Corp.'s Q1 2024 Earnings (NASDAQ:PROF)

September 21, 2023 | finance.yahoo.com

Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

September 19, 2023 | financialpost.com

Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference

September 19, 2023 | americanbankingnews.com

Profound Medical (NASDAQ:PROF) Upgraded at Raymond James

September 6, 2023 | finance.yahoo.com

Profound Medical Announces At-the-Market Offering of up to US$30,000,000

August 22, 2023 | seekingalpha.com

PROF Profound Medical Corp.

August 9, 2023 | finance.yahoo.com

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

July 15, 2023 | fool.com

Profound Medical (NASDAQ: PROF)

July 12, 2023 | msn.com

Knoxville boy who survived and thrived despite profound medical odds dies at age 12

June 22, 2023 | msn.com

Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%

June 6, 2023 | finance.yahoo.com

Profound Medical Gains 16%, Insider Trades Reap Benefit

May 23, 2023 | msn.com

What Makes Profound Medical (PROF) a New Buy Stock

May 10, 2023 | msn.com

Profound Medical: Q1 Earnings Insights

May 10, 2023 | finance.yahoo.com

Profound Medical Announces First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Individual investors account for 45% of Profound Medical Corp.'s (TSE:PRN) ownership, while institutions account for 39%

April 26, 2023 | theglobeandmail.com

Closing Bell: Profound Medical Corp down on Wednesday (PRN)

April 25, 2023 | theglobeandmail.com

Closing Bell: Profound Medical Corp down on Tuesday (PRN)

April 21, 2023 | theglobeandmail.com

Closing Bell: Profound Medical Corp up on Friday (PRN)

April 20, 2023 | marketwatch.com

Profound Medical to Release First Quarter 2023 Financial Results on May 10 - Conference Call to Follow

April 19, 2023 | theglobeandmail.com

Closing Bell: Profound Medical Corp up on Tuesday (PRN)

See More Headlines

Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

PROF Company Calendar

Last Earnings: 8/09/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PROF
CUSIP: N/A
CIK: 1628808
Web: www.profoundmedical.com
Phone: (647) 476-1350
Fax: 64-7847-3739
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.63
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $6.50
Forecasted Upside/Downside: +28.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,670,000.00
Net Margins: -423.75%
Pretax Margin: -418.97%
Return on Equity: -55.78%
Return on Assets: -46.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.98
Quick Ratio: 4.25

Sales & Book Value

Annual Sales: $6.68 million
Price / Sales: 31.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.49 per share
Price / Book: 3.95

Miscellaneous

Outstanding Shares: 21,370,000
Free Float: 21,041,000
Market Cap: $210.28 million
Optionable: Optionable
Beta: 0.80

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Arun Swarup Menawat MBA (Age 68)
Ph.D., Chairman & CEO
Comp: $551.88k

Mr. Rashed Dewan (Age 55)
Chief Financial Officer
Comp: $250.37k

Mr. Hartmut Warnken (Age 50)
Chief Commercial Officer of Outside US
Comp: $224.93k

Dr. Mathieu Burtnyk (Age 41)
Sr. VP of Product Leader TULSA-PRO
Comp: $246.1k

Mr. Abbey Goodman (Age 40)
Chief Commercial Officer of US
Comp: $353.75k

Mr. Stephen Kilmer
Investor Relations

Mr. Jacques F. Cornet (Age 67)
Sr. VP & Product Leader Sonalleve

Mr. Matthew Sobczyk C.A.
CPA, Assistant Corp. Controller

Mr. Levant Tinaz
Software Developer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PROF Stock - Frequently Asked Questions

Should I buy or sell Profound Medical stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PROF shares.
View PROF analyst ratings or view top-rated stocks.
What is Profound Medical's stock price forecast for 2023?: 3 brokerages have issued 1-year target prices for Profound Medical's stock. Their PROF share price forecasts range from $6.50 to $20.00. On average, they predict the company's share price to reach $12.63 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for PROF or view top-rated stocks among Wall Street analysts.
How have PROF shares performed in 2023?: Profound Medical's stock was trading at $10.89 at the beginning of 2023. Since then, PROF shares have decreased by 9.6% and is now trading at $9.84.
View the best growth stocks for 2023 here.
When is Profound Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PROF earnings forecast.
How were Profound Medical's earnings last quarter?: Profound Medical Corp. (NASDAQ:PROF) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $2.05 million. Profound Medical had a negative trailing twelve-month return on equity of 55.78% and a negative net margin of 423.75%.

What is Profound Medical's stock symbol?: Profound Medical trades on the NASDAQ under the ticker symbol "PROF."
How do I buy shares of Profound Medical?: Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Profound Medical's stock price today?: One share of PROF stock can currently be purchased for approximately $9.84.
How much money does Profound Medical make?: Profound Medical (NASDAQ:PROF) has a market capitalization of $210.28 million and generates $6.68 million in revenue each year. The company earns $-28,670,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.
How many employees does Profound Medical have?: The company employs 131 workers across the globe.
How can I contact Profound Medical?: Profound Medical's mailing address is 2400 SKYMARK AVENUE UNIT 6, MISSISSAUGA A6, L4W 5K5. The official website for the company is www.profoundmedical.com. The company can be reached via phone at (647) 476-1350, via email at skilmer@profoundmedical.com, or via fax at 64-7847-3739.

This page (NASDAQ:PROF) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial